MIST · XBRL financial data

Milestone Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MIST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	34,488	38,671	39,829	31,052	14,357	18,108
General and administrative	10,285	12,399	15,718	15,932	16,742	17,274
Operating income (loss)	(50,710)	(43,073)	(59,642)	(61,098)	(42,102)	(62,140)
Interest income	—	—	—	3,967	4,164	2,920
Interest expense	—	—	—	2,554	3,581	3,838
Income tax expense (benefit)	(17)	—	—	—	—	—
Net income (loss)	(49,967)	(42,853)	(58,388)	(59,685)	(41,519)	(63,058)
Earnings per share, basic USD per share	(1.70)	(1.02)	(1.38)	(1.39)	(0.67)	(0.75)
Earnings per share, diluted USD per share	(1.70)	(1.02)	(1.38)	(1.39)	(0.67)	(0.75)

Fiscal years (MIST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	72,310	114,141	7,636	13,760	25,314	73,046
Short-term investments	70,000	0	56,949	52,243	44,381	32,914
Inventory	—	—	—	—	—	648
Total current assets	148,686	118,923	71,803	73,032	73,926	111,921
Property and equipment, net	308	215	257	277	197	511
Right-of-use asset	980	711	2,423	1,917	1,376	1,129
Total assets	149,974	119,849	74,483	75,226	75,499	113,561
Accounts payable	—	—	—	—	—	5,645
Accrued liabilities	—	—	—	—	—	7,644
Total current liabilities	6,159	6,775	6,139	7,226	8,126	13,979
Lease liability, non-current	696	474	1,996	1,457	874	539
Total liabilities	6,855	7,249	8,135	58,455	62,352	71,792
Accumulated deficit	(163,466)	(206,319)	(266,341)	(326,026)	(367,545)	(430,603)
Total stockholders' equity	143,119	112,600	66,348	16,771	13,147	41,769
Total liabilities and equity	149,974	119,849	74,483	75,226	75,499	113,561
Common shares outstanding (cover page) thousands of shares	29,846	29,917	33,287	53,150	53,354	117,667

Fiscal years (MIST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(49,967)	(42,853)	(58,388)	(59,685)	(41,519)	(63,058)
Stock-based compensation	4,945	7,279	9,048	9,534	5,776	7,461
Depreciation and amortization	97	93	89	92	105	114
Net cash from operating activities	(50,732)	(33,224)	(52,469)	(46,424)	(28,848)	(49,041)
Purchases of property and equipment	—	—	272	112	33	302
Net cash from investing activities	(70,000)	70,000	(57,124)	4,756	8,283	11,246
Proceeds from issuing common stock	24,917	—	2,630	—	27,258	37,593
Net cash from financing activities	73,224	5,055	3,088	47,792	32,119	85,527
Net change in cash	(47,508)	41,831	(106,505)	6,124	11,554	47,732

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Milestone Pharmaceuticals	169,728	559	(22,714)*	124.5M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Assembly Biosciences	32,286	not reported	(15,488)*	20.4M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
DiaMedica Therapeutics	5,129	not reported	(8,114)*	53.9M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Ironwood Pharmaceuticals	79,127	113,041	58,276*	165.2M	—	Q2 FY26 10-QJun 30, 2026
Vaxart	50,929	27,185	2,778*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Larimar Therapeutics	92,687	not reported	(44,030)*	103.9M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Achieve Life Sciences	47,958	not reported	(10,777)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.